AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02606500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elonva
Description: 20 obese women will be the study group and 20 normal weighing women will be the control group. Both groups will receive 150 mcg of Elonva for controlled ovarian hyperstimulation (COH). Gonadotropin-releasing hormone (GnRH) antagonist will be used to prevent premature luteinizing hormone (LH) surge. Additional daily doses of 200 IU of recombinant follicle stimulating hormone (rFSH) will be used if necessary. Human chorionic gonadotropin (hCG) will be used for oocyte maturation. 2 mature follicles will be aspirated separately in each patient. Cumulus cell (CC) samples will be collected and stored on -80 oC for subsequent analysis. Clinical and molecular parameters of IVF success will be assessed and compared between the groups.~The exclusion criteria will be: polycystic ovary syndrome, severely abnormal sperm parameters, and age > 38 years.
Study NCT02606500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elonva
Description: 20 obese women will be the study group and 20 normal weighing women will be the control group. Both groups will receive 150 mcg of Elonva for controlled ovarian hyperstimulation (COH). Gonadotropin-releasing hormone (GnRH) antagonist will be used to prevent premature luteinizing hormone (LH) surge. Additional daily doses of 200 IU of recombinant follicle stimulating hormone (rFSH) will be used if necessary. Human chorionic gonadotropin (hCG) will be used for oocyte maturation. 2 mature follicles will be aspirated separately in each patient. Cumulus cell (CC) samples will be collected and stored on -80 oC for subsequent analysis. Clinical and molecular parameters of IVF success will be assessed and compared between the groups.~The exclusion criteria will be: polycystic ovary syndrome, severely abnormal sperm parameters, and age > 38 years.
Study NCT01501942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide
Description: AIM-102 is supplied as an oral solution. Dose is 15 mg of AIM-102 per kg of patient weight measured on Treatment Day 1 of each treatment phase The study drug will be administered for 4 consecutive days with at least a 2 week wash-out period prior to crossing over to the alternative treatment for 4 days.
Study NCT01501942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buffered Saline
Description: The matching placebo is an oral solution of phosphate buffered saline
Study NCT04192500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVX836
Description: One single administration intramuscularly at Day 1.
Study NCT04192500 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent seasonal influenza vaccine (Influvac TetraTM)
Description: One single administration intramuscularly at Day 1.
Study NCT00565305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Touch
Description: Healing Touch (HT) is a non-invasive therapeutic approach to healing which describes its mode of action as using touch to modulate the patient's energy system. The goal of HT is to restore harmony and balance in the patient's energy system to assist the person to self-heal.88 Healing Touch, as used here, refers to the techniques taught in Mentgen's standardized curriculum of Healing Touch offered through Healing Touch International and endorsed by the American Holistic Nurse's Association
Study NCT00565305 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: 4-6 cycles of cytotoxic chemotherapy followed by 5040 cGy of external beam whole breast radiotherapy in 28 fractions usually followed by a boost of 1000-1600 cGy
Study NCT00565305 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: 4-6 cycles of cytotoxic chemotherapy followed by 5040 cGy of external beam whole breast radiotherapy in 28 fractions usually followed by a boost of 1000-1600 cGy
Study NCT02846948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused assessed echocardiography
Description: Focused assessed transthoracic echocardiography is non-invasive, painless procedure. The transducer is placed on the chest at certain locations and angles to get the required information on patient's condition.
Study NCT00861809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 25 mg
Description: 25 mg
Study NCT00861809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo comparator
Study NCT00861809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 50 mg
Description: 50 mg
Study NCT00861809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 1250 mg
Description: 125 mg
Study NCT04659538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAPTIS Embolic Protection device
Description: The CAPTIS Embolic Protection device will be deployed during standard of care TAVR procedure. The device's safety will be assessed up to one month post procedure. The device's technical performance and feasibility to capture and remove debris during the procedure will be evaluated.
Study NCT02403700 — intervention group
Intervention type: DEVICE
Intervention: Cone beam computed tomography (CBCT)
Description: Dimensional changes are documented over a healing period of 8-weeks following single tooth extraction. To document these changes over time, two methods will be applied. Firstly, two cone beam computed tomographies (CBCT) will be obtained, one directly after tooth extraction, the other one at 8 weeks of socket healing prior to implant placement. The two CBCT's will be analyzed with a novel software program (InVivo Dental). Secondly, consecutive impressions will be made at day 0 (day of extraction), day 14, 28, 42, and 56 to digitally produce virtual 3D study models. These models can be analyzed with another software program (Geomagic Studi 10) to document the variations of the soft tissue in the extraction site.
Study NCT03186066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flamingo Device
Description: Endoscopic Treatment of Buried Bumper Syndrome with the Flamingo Device
Study NCT03186066 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Endoscopic Treatment of Buried Bumper Syndrome with an endoscopic submucosal dissection knife
Study NCT00622609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK249320A
Description: GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump.
Study NCT00622609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride intravenous infusion will be given as matching placebo.
Study NCT01310296 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lofexidine hydrochloride
Description: Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
Study NCT01310296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine hydrochloride
Description: Single Dose = 200 μg lofexidine in phosphate-buffered saline administered intravenously via infusion pump at a rate of 1 μg/min for 200 min
Study NCT04230226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pre-workout plus and protein recovery plus
Description: Study products consumed prior and after exercise
Study NCT04230226 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product consumed prior and after exercise
Study NCT00938210 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Laparoscopic colonic surgery
Description: Laparoscopic removal of colonic cancer
Study NCT01567956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionyl-L-Carnitine
Description: 500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks
Study NCT01567956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
Study NCT03708211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931 PIC
Description: TAK-931 PICs.
Study NCT03708211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931 Tablet
Description: TAK-931 Tablets.
Study NCT03708211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole Tablets.
Study NCT01975805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Study NCT01975805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Povidone Iodine
Study NCT03059862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-tryptophan
Description: 3 g/day of L-tryptophan added to the standardized low-tryptophan diet. Duration: 3 weeks.
Study NCT03059862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be added to the standardized low-tryptophan diet. Duration: 3 weeks.
Study NCT00097695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: 30 mg (3mL) subcutaneous icatibant injection in the abdominal region
Study NCT00097695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection, matched to study drug Single dose: 3 mL
Study NCT02689908 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: computed tomography
Description: low dose protocol of thorax ct
Study NCT01124149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMX mesalamine/ mesalazine
Description: 4.8g/day given QD (four 1.2g tablets) for 8 weeks, 2.4g/day given QD (two 1.2g tablets) for 12 months
Study NCT03236857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Dexamethasone and/or vincristine and/or pegasparaginase OR cytarabine and/or etoposide and/or pegasparaginase; tyrosine kinase inhibitor; cytarabine OR azacitidine OR decitabine; rituximab and/or dexamethasone and/or vincristine; cyclophosphamide and/or topotecan
Study NCT03236857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Oral tablet for participants; Tablet for oral suspension (participants who cannot swallow a tablet)
Study NCT00169533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW572016 oral tablets
Description: Lapatinib either at 750, 1000, 1250 or 1500 mgs
Study NCT00995553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: This is an adaptive, computer-based cognitive training intervention. Participants will complete 3 1-hour cognitive training sessions focused on attention and working memory processes weekly for 4 months.
Study NCT00995553 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer Skills
Description: This is a computer-based course in which participants will be taught how to use Microsoft Office applications and typing skills. Participants will attend a 1-hour course three times a week four 4-months.
Study NCT01226069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerine Magnesium sulphate paste
Description: Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
Study NCT01226069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mucopolysaccharide polysulphate
Description: Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
Study NCT01226069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No application
Description: No application
Study NCT00788125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00788125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Study NCT00788125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Study NCT00788125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT00788125 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Study NCT00788125 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Study NCT00788125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00788125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00788125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT00788125 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03006016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid
Description: The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
Study NCT03006016 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
Study NCT03715270 — intervention group
Intervention type: DEVICE
Intervention: Image surgical area
Description: Image surgical area
Study NCT03427970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: observation
Description: Control group will receive the standard of care according to the Scoliosis Research Society criteria: observation for patients with curves between 10°- 25°.
Study NCT03427970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: three-dimensionally integrated exercise for scoliosis
Description: Experimental group will receive a modified physiotherapeutic scoliosis specific exercises --the three-dimensionally integrated exercise for scoliosis program, which include auto-correction in 3D, postural correction, breathing training, resistance training, muscle fascia releasing, functional activities, balance training, core stability training, proprioceptive input exercises and patient education. Auto-correction exercise in 3D will combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.
Study NCT02152878 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: For sham tDCS, the device will be turned off after 30 seconds of stimulation.
Study NCT02152878 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active stimulation
Description: For active tDCS, we will place the anode and the cathode over the left and right dorsolateral prefrontal cortex areas, respectively (corresponding to F3 and F4 according to the EEG 10-20 system). We will use 5x5 cm electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup and has been previously used in major depression trials
Study NCT00991848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: received 240 mg lidocaine diluted in 125 mL 0.9% saline.
Study NCT02596503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Intravenous eribulin administered on days 1 and 8 of a 21-day cycle.
Study NCT02596503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered orally at a fixed dose of 90 mg/m2/day on days 1 -5 of a 21-day cycle.
Study NCT02596503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: Cefixime will be given to all patients to reduce irinotecan-associated diarrhea. It will be administered Day -1 through Day 8 of each cycle.
Study NCT01459874 — intervention group
Intervention type: BEHAVIORAL
Intervention: Organizational model for remote monitoring
Description: An organizational model defining roles and behaviors of subjects involved in the remote monitoring of pacemaker and defibrillator recipients
Study NCT01706926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 30 mg
Description: Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks
Study NCT01706926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 100 mg
Description: Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks.
Study NCT01706926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 150 mg
Description: Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks.
Study NCT01706926 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks.
Study NCT02287532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIABEO software
Description: DIABEO is an electronic diary system incorporating an immediate automatic aid to calculating the insulin dose according to the prescription given by the doctor, and a data processing, automated analysis message and secure internet data transfer system. DIABEO software could be combined with remote paramedical monitoring of data (telemonitoring)
Study NCT01779622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal
Description: Ingestion of mixed meal
Study NCT03328793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mood Assessment
Description: Prior to and after the session, the patients will be asked to fill a VAMS (Visual Analog Mood Scale).
Study NCT03328793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood Assessment
Description: Prior to and after the session, the patients will be asked to fill a VAMS (Visual Analog Mood Scale).
Study NCT03328793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotion Assessment
Description: During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the Observed Emotional Rating Scale (OERS), the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
Study NCT03328793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Assessment
Description: During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the Observed Emotional Rating Scale (OERS), the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
Study NCT03328793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communication Assessment
Description: During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the CODEM Scale, the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
Study NCT03328793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Assessment
Description: During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the CODEM Scale, the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
Study NCT03328793 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobility assessment
Description: If deemed to be safe, the patients will undergo a gait speed assessment as well as a TUG (timed-up-and-go) prior to and after the sessions
Study NCT03328793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobility assessment
Description: If deemed to be safe, the patients will undergo a gait speed assessment as well as a TUG (timed-up-and-go) prior to and after the sessions
Study NCT03328793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: The participants will listen to a 30 minute live music sessions which will be given by musicians (who is a volunteer)
Study NCT03328793 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Documentary watching
Description: The patients will watch a documentary for 30 minutes in the presence of a volunteer
Study NCT00922909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simon task
Description: Reaction time task
Study NCT01220830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytotron
Description: Exposure to RFQMR with Cytotron for 28 consecutive days for one hour daily.
Study NCT04439656 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Eye movement analysis
Description: Eye movements will be analyzed to identify if seizures are present and compared to the EEG read